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 Infla atory Bo el isease
  
1. Introduction
Inflammatory bowel disease (IBD) is a collection of inflammatory forms of the colon and small 
intestine (Figure 1).
Under this umbrella is Crohn’s disease (CD) and ulcerative colitis (UC) which they are the 
main types of it. Crohn’s disease affects the gastrointestinal tract from the mouth to the anus, 
whereas ulcerative colitis principally affects the colon and the rectum [1]. A third type of 
bowel inflammation had emerged known as indeterminate colitis (IC) or inflammatory bowel 
Figure 1. Colonic biopsy of the mucosa shows numerous neutrophils within the crypt and several eosinophils.
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disease unclassified (IBDU) when the differentiation between UC and CD is difficult due to 
the absence of standard golden test that differentiates between these two diseases [2]. IBD can 
affect any age of the population, but it is more common between 15 and 40 years of age (both 
young adults and elderly). About 7–20% of IBD patients are children and 60–85% are adults 
below 40 years of age [3]. There is a bimodal distribution of CD in American cohort popula-
tion and European and Canadian population; the peak incidence of CD is 15–29 years of age, 
while the incidence of UC is 20–29 years of age [4]. In smokers, the onset of UC is at later years 
of age compared to non-smoker patients [5]. Hospital admissions of the patients who were 
over the age of 65 years of age represent 25% of all hospital admissions for IBD patients [6].
2. Signs and symptoms
Inflammation anywhere along the gastrointestinal tract disrupts the normal mucosal integ-
rity. Thus, IBD can be very painful and disruptive, and it may be life-threatening in some 
cases. The symptoms are vary from abdominal pain, cramps, swelling in the stomach, recur-
ring or bloody diarrhea, weight loss, tiredness, fever, vomiting, anemia. Other rare symptoms 
are joint pain, painful red eyes, painful red skin nodules, and jaundice. The characters of these 
symptoms are remission and relapse [7].
3. Causes
The precise cause is unknown, and it may be due to interaction between environmental and 
genetic factors leading to immunological responses and inflammation in the intestine.
Figure 2. Loci associated with IBD. Pink genes are in IBD-associated loci, blue are not [8].
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3.1. Genetic factor
It is more likely to develop IBD if it has a sibling or parent with the IBD. There are about 163 
loci that are related to 300 known genes related to cytokine production, lymphocyte activa-
tion, and the response to bacterial infection. The most important genes are NOD2, Il10, and 
CARD9 that had a relation with bacterial interaction and gene HCK which had an important 
role in anti-inflammation (Figure 2) [8].
4. Environmental factors
4.1. Microbiota
The gastrointestinal tract contains many microbiota that maintain normal symbiosis. 
When there is an alteration in this enteral bacteria may leads to gut inflammation [9]. 
About 30–50% reduction in Lachnospiraceae and Bacteroides in the gut of IBD patients and 
have been prescribed antibiotics for them in the last 2–5 years ago [10]. These drugs in 
association with other types of food like concentrated milk fat can alter the commensalism 
bacteria in the gut [11].
4.2. Intestinal barrier
Intestinal epithelial mucosa is an important innate immune mechanism that acts as a barrier 
preventing microbial gut from invading the epithelial tissue [12]. Changes in intestinal micro-
organisms lead to uncontrolled immune response that leads to damage this barrier through 
dysfunctioning of TLR signaling and invading of bacteria initiating an inflammatory immune 
response [13]. The immune system protects the gut from pathogen like bacteria and virus that 
leads to inflammation in the digestive tract.
4.3. Diet
The type of diet is an important factor in initiation of IBD [14]. It had been found that 
animal protein in meat and fish is associated with UC, while plant protein had no effect 
due to the presence of sulfur-containing amino acid like methionine [15]. Diet containing 
either intact proteins or free amino acids like elemental, semielemental, and polymeric 
diets during intestinal inflammation may lead to immunological changes like decrease of 
serum IgG; increase in the production of IL-6, IL-17A, TGF-β, and IL-10 in the small and 
large intestines; increase in intestinal permeability; increased number of total and activated 
CD4+ T helper cells in the small intestine; and proliferating cells in the colon. So, the design 
of nutritional therapeutic intervention for inflammatory bowel diseases may contribute in 
the treatment [16]. Eating habit is an important factor in initiation IBD especially in west-
ern countries like imbalance in the ratio of n-6/n-3 polyunsaturated fatty acids (PUFAs) in 
favor of n-6 PUFAs, and a higher ratio of n-6 PUF versus n-3 PUF was associated with an 
increased UC incidence [17].
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5. Risk factors of IBD
5.1. Smoking
Smoking is one of the most important risk factors for developing Crohn’s disease but in ulcer-
ative colitis affects non-smokers and ex-smokers. Smoker patients will be affected later on 
than non-smoker ones [5].
5.2. Ethnicity
Certain ethnic groups like Caucasians and Ashkenazi Jews have a higher risk for developing 
IBD. Non-Caucasians had more severe disease performance than Caucasians. Non-Central 
European descent patients who were born in Europe were diagnosed at lower years of age 
with this disease than those born outside Europe and migrated to The Netherlands [18].
5.3. Age
IBD can occur at any age group, but mainly it starts before the age of 35 [19].
5.4. Family history
Individuals whose parents, sibling, or child have IBD are at a much higher risk of developing 
IBD. So genetic with epidemiological factors could be used as predictors of the disease course. 
For example, ileal localization of CD patients was more common in NOD2-variant carriers 
and IL-6 GC + CC genotypes, identifying C allele as a probable marker of increased risk for 
ileal CD and earlier onset of the disease in CD patients with a positive family history for 
IBD. Patients with CD who are TLR4 299Gly carriers are at higher risk for surgery compared 
with TLR4 299Asp-variant-carrier patients [20].
5.5. Geographical region
Population who live in urban areas and industrialized countries are more liable to develop 
IBD because they tend to eat more fat and processed food. In addition to that, IBD is more 
common among people living in northern cold climates. The incidence and prevalence of 
inflammatory bowel disease show different variations in different geographical regions. IBD 
is more common in North America and Northern and Western Europe; later on, the incidence 
was increased in Eastern European and Asian countries [21].
5.6. Gender
IBD affects both sexes equally. Ulcerative colitis is more common among males, while Crohn’s 
disease is more common among females.
6. Complications of IBD
• Malnutrition with resulting weight loss. The frequency of malnutrition in patients with in-
flammatory bowel disease was high. One of the predictive factors of malnutrition is avoidance 
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of some foods during flares which were associated with higher risk of malnutrition, and many 
patients had self-imposed food restrictions depending on their beliefs and thoughts [22].
• Colon cancer and other types of tumors. IBD diagnosis at an advanced age had an associa-
tion with colitis-associated colorectal cancer. Using chemotherapy like thiopurine in older 
IBD patients leads to an increased risk of non-Hodgkin’s lymphoma, nonmelanoma skin 
cancer, and urinary tract cancers. Furthermore, older age group is accompanied by multi-
morbidity factors like malnutrition and decreased life expectancy. This needs good cancer 
screening and medical treatment [23].
• Fistulas or ulcers that go through the bowel wall creating a hole between different parts 
of the digestive tract that need surgical intervention [24]. The rate of abdominal surgery 
has decreased and reserved for severe and complicated IBD disease complications due 
to advances in medical therapy, surveillance, and management methods. The emergency 
surgery stills in the same rates and increases in surgical recurrence in spite of the reduction 
in surgical rate morbidity [25].
• Intestinal rupture or spontaneous perforation of the small intestine is rare but can occur in 
the clinical course of Crohn’s disease [26].
• Bowel obstruction. Whether intestinal or colonic obstruction is troublesome for neoplasm as 
the first clinical manifestation of IBD. This is a clinical thing for surgeons, pathologist, and 
gastroenterologist to be alert of this. The management of these lesions is surgery like hemico-
lectomy, segmental colonic resection of the portion involved according to the condition [27].
• Blood loss. One of the complications of IBD is bleeding per rectum or bloody diarrhea that 
leads to shock [28].
7. Diagnosis
This can be achieved starting from history about chief complain ending with family history. 
This followed by physical examination and laboratory tests:
1. Stool sample: To diagnose the causative microbial agent that causes the disease using fecal 
samples and assess disease severity. IBD is associated with alteration in the gut microbiota 
(gut dysbiosis). Bacteria that produce urease leads to transfer of nitrogen to the gut micro-
biota that is used for amino acid synthesis resulting in a predominance of Proteobacteria 
species and dysbiosis. A possible role for altered urease expression and nitrogen flux in the 
development of gut dysbiosis suggests that bacterial urease may be a likely therapeutic tar-
get for inflammatory bowel diseases [29]. Other fecal tests are S100A12, neopterin, elastase, 
fecal hemoglobin, alpha-1 antitrypsin, gelatinase-associated lipocalin, chitinase-3-like-1 
protein, matrix metalloproteinase-9, lysozyme, M2 pyruvate kinase, myeloperoxidase, fe-
cal eosinophil proteins, beta-defensin-2, and beta-glucuronidase. Some of them had high 
sensitivity and specificity and correlated with disease activity and response to therapy, 
and another test is mucosal healing. Fecal calprotectin or fecal lactoferrin is the typical test 
for assessing IBD activity, even though its specificity and sensitivity are not optimal and it 
does not have a validated cutoff [30].
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2. Blood test: There is a panel of blood tests in diagnosis and screening for ulcerative colitis and 
Crohn’s disease like hemoglobin, platelet count, erythrocyte sedimentation rate (ESR), C-re-
active protein (CRP), and albumin are widely used [31]. Other laboratory tests have been in-
cluded like interleukin-1 receptor antagonist, eotaxin, anti-neutrophil cytoplasmic and anti-
Saccharomyces cerevisiae antibodies, tumor necrosis factor alpha, and thrombopoietin [32–36].
3. Plain film and barium X-ray (follow-through and enema): Plain X-ray can be used when 
perforation is suspected. Barium X-ray demonstrates the site and the severity of the lesion 
in the large and small intestine. It also tracks the movement of a thick, chalky liquid barium 
through the intestines [37].
4. Flexible sigmoidoscopy and colonoscopy: This is a direct visualization to sigmoid colon 
for any ulcers, fistula, and other lesions with biopsy taken. Colonoscopy surveillance is 
used for early dysplasia detection and treatment, thus preventing progression to colorectal 
cancer. Techniques and technologies are available to enhance optical diagnosis of dyspla-
sia in inflammatory bowel disease [38].
5. Capsule endoscopy: Colon capsule endoscopy is a wireless and simply invasive method 
for direct visualization of the whole colon and small intestine, screening and monitoring 
disease activity in inflammatory bowel diseases [39]. The diagnosis of IBD using a pan-
enteric video capsule endoscope that visualizes both the small and large bowels is more 
higher than ileocolonoscopy in patients with active disease [40].
6. Computer tomography (CT) and magnetic resonance imaging (MRI): Used to examine 
the small intestine and detect any complications of IBD like abscesses, fistulas, and intes-
tinal obstruction. It also excludes other conditions that cause symptoms similar to those 
associated with IBD like appendicitis. The patient usually drinks an oral contrast, and 
intravenous contrast may also be injected into a vein prior to the test. Magnetic resonance 
(MR) enterography has the advantage over other methods of being detection active inflam-
mation noninvasive, lacking ionizing radiation, and demonstrating excellent soft tissue 
contrast to evaluate patients with inflammatory bowel disease [41].
8. Treatment
1. Anti-inflammatory drugs that decrease inflammation of gut mucosa in spite of its side 
effect like sulfasalazine and corticosteroids. Sulfasalazine is a sulfa antimicrobial that is 
used not only to treat IBD that affects gut microbes in the fecal samples by the increas-
ing amount of SCFA-producing bacteria and lactic acid-producing bacteria as well as the 
decreasing amount of Proteobacteria but also to modulate the dysregulated function of the 
TNBS-induced colitis, increased capacity for carbohydrate metabolism and citrate cycle, 
and a decrease in the oxidative stress of riboflavin, sulfur, cysteine as well as bacterial 
pathogenesis like cell motility and secretion, bacterial motility proteins, and flagellar as-
sembly. Furthermore, a higher proportion of Mycoplasma concentration [42].
2. Immunosuppressant drugs (immunomodulators): It acts on immune response preventing 
it from attacking the bowel and causing inflammation like anti-TNF antibodies (infliximab) 
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(IFX). Some patients will respond to this treatment, while others will not. The transmem-
brane TNF-α might be linked to response to IFX by promoting reverse signaling-induced 
apoptosis in inflammatory cells. The percentage of tmTNF-α bearing lymphocytes and 
monocytes and the intensity of tmTNF-α in the circulating leukocyte were directly related 
to primary response to IFX. Immunosuppressants have many side effects including rashes 
and infections [43].
3. Antibiotics: The pathogenesis of inflammatory bowel disease is complex and involves the 
interaction between genetic and environmental factors. One modality is prescription of 
antibiotic like oral vancomycin with or without gentamicin that targets and kill Gram-
negative and anaerobic bacteria that may trigger or aggravate IBD symptoms [44].
4. Antidiarrheal drugs and laxatives: Diarrhea is a common clinical symptom of inflamma-
tory bowel diseases with abdominal pain, urgency, and fecal incontinence. The pathophys-
iology of it is due to a defect in absorption of salt and water by the inflamed bowel with in-
flammation. So, one mode of treatment is antidiarrheal drugs to treat IBD symptoms [45].
5. Lifestyle choices: IBD is increased in both developed and developing countries due to 
lifestyle which is important in patients with IBD like obesity which is increased in parallel 
with IBD. The possible cause is due to adipose tissue that produces pro-inflammatory adi-
pokines and provides a possible mechanism for the links between obesity and IBD. Other 
possible methods of lifestyle are drinking plenty of fluids, which helps to compensate for 
those lost in stool, and vitamin and mineral supplements, which can help in patients with 
nutritional deficiencies. Avoiding dairy products and stressful situations also improves 
symptoms. Exercising and quitting smoking can improve the IBD [46].
6. Surgery can sometimes be necessary for people with IBD, like strictureplasty, to widen a 
narrowed bowel, closure or removal of fistulas, removal of affected portions of the intes-
tines, and removal of the entire colon and rectum, for severe cases of ulcerative colitis [47].
8.1. Prevention
The hereditary causes of IBD cannot be prevented. However, you may be able to reduce 
your risk of developing IBD or prevent a relapse [48]. This can be achieved by eating healthy 
foods like regular consumption of extra virgin olive oil, which is the main source of fat in the 
Mediterranean diet [49]. Other methods are exercising regularly and quit smoking. In addi-
tion to that, using infliximab helps to prevent recurrence [50].
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